|
SLC35A5 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.66239999987994E-07 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
3.50049999999769E-05 |
| Normal-vs-Stage2 |
4.26009999999755E-05 |
| Normal-vs-Stage3 |
1.5447000001334E-07 |
| Normal-vs-Stage4 |
1.31950000037406E-07 |
| Stage1-vs-Stage2 |
1.672190E-01 |
| Stage1-vs-Stage3 |
4.178400E-02 |
| Stage1-vs-Stage4 |
1.896160E-02 |
| Stage2-vs-Stage3 |
9.254200E-01 |
| Stage2-vs-Stage4 |
4.736000E-01 |
| Stage3-vs-Stage4 |
4.506600E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
5.2439000031157E-08 |
| Normal-vs-AfricanAmerican |
1.558250E-02 |
| Normal-vs-Asian |
6.243900E-03 |
| Caucasian-vs-AfricanAmerican |
3.729600E-01 |
| Caucasian-vs-Asian |
1.516620E-01 |
| AfricanAmerican-vs-Asian |
8.778800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
3.91179999503777E-09 |
| Normal-vs-Female |
3.90179999998352E-06 |
| Male-vs-Female |
2.390300E-02 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
2.197800E-04 |
| Normal-vs-Age(41-60Yrs) |
4.51679999957655E-07 |
| Normal-vs-Age(61-80Yrs) |
5.20120000402358E-08 |
| Normal-vs-Age(81-100Yrs) |
1.589890E-02 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
1.416780E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
1.762060E-02 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
4.235400E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
2.195200E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
7.123000E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
9.330400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
8.679700E-03 |
| Classical-VS-Follicular |
4.019900E-02 |
| Classical-VS-Other |
1.843350E-01 |
| Classical-VS-Normal |
3.58850000000688E-05 |
| Tall-VS-Follicular |
4.599400E-01 |
| Tall-VS-Other |
7.502400E-01 |
| Tall-VS-Normal |
6.16719999957382E-07 |
| Follicular-VS-Other |
5.838800E-01 |
| Follicular-VS-Normal |
3.75559999998831E-06 |
| Other-VS-Normal |
6.995600E-03 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
2.5046999996281E-07 |
| Normal-vs-N1 |
1.62928999999368E-05 |
| N0-vs-N1 |
5.926000E-01 |
|
|
